ROCKVILLE, MD and KYOTO, JAPAN, Jul 28 (MARKET WIRE)
--
Seegene, Inc. and Shimadzu Corporation today announced a strategic
partnership to combine Seegene's Seeplex(R) multi-pathogen tests with
Shimadzu's MultiNA (1) analytical platform. Under terms of the deal,
Shimadzu and Seegene will collaborate on integrating the Seeplex
polymerase chain reaction-based tests with Shimadzu's MultiNA high-speed
electrophoresis system to provide a highly sensitive, high-throughput
multi-pathogen detection and analysis solution.
"This strategic agreement reinforces our plan to bring solutions, and not
only products, to our customers," said Dr. Jong-Yoon Chun, Founder and
Chief Executive Officer, Seegene. "Shimadzu's MultiNA is outstanding in
the market for electrophoresis analysis and a perfect match for the
Seeplex family of multi-pathogen tests."
"Seegene's novel multi-pathogen detection test working with Shimadzu's
next-generation electrophoresis systems creates an unparalleled screening
platform for laboratories around the world," said Yoshiyuki Togawa,
General Manager, Shimadzu. "Seeplex tests running on MultiNA is the fast,
accurate and efficient way for laboratories to screen for the most
rampant and debilitating pathogens infecting people around worldwide."
Shimadzu's MultiNA is a microchip electrophoresis system that quickly and
easily performs DNA and RNA nucleic acid size confirmation and
quantification. The system uses microchip technology to conduct fully
automated high-speed electrophoresis separation, and fluorescence
detection to perform high-sensitivity analysis.
Seeplex tests are based on a breakthrough multiplexing PCR technology
capable of detecting multiple pathogens in a single tube. Seeplex-based
tests deliver maximum specificity, reproducibility and sensitivity and can
be applied to a broad range of molecular diagnostics, including human,
animal, plant and microorganism. Currently, Seegene's Seeplex
multi-pathogen detection tests offer labs worldwide simple, cost-effective
and comprehensive screening for STDs, respiratory viruses, human
papillomaviruses, sepsis and pneumonia.
(1) MultiNA is Research Use Only.
About Shimadzu
Founded in 1875, Shimadzu Corporation develops and manufactures analytical
and monitoring equipment for science laboratories worldwide. Its products
include imaging systems for medical diagnosis such as ultrasound systems
and mobile X-ray systems, as well as spectrophotometers and chromatography
systems for the life science sector. For more information about Shimadzu's
extensive line of laboratory offerings, please visit www.shimadzu.com.
About Seegene
Seegene, Inc. is pioneering the field of multi-pathogen testing. Seegene
applies its novel and proprietary Seeplex system utilizing "DPO (Dual
Priming Oligo)" and "ACP (Annealing Control Primer)" to create
multi-pathogen tests delivering maximum specificity, reproducibility and
sensitivity. With over 360 citations and several patents and patents
pending, Seegene has been offering advanced molecular diagnostics services
to over 1,200 major global institutes in more than 30 countries. Seegene
is actively working with both the scientific and OEM business community.
Seegene's mission is to integrate Seeplex with disease diagnostics to
provide a new guideline for effectively treating patients. Seegene was
founded in 2000 and is based in Rockville, MD and Seoul, Korea. For more
information please visit www.seegene.com.
All trademarks and registered trademarks are property of their respective
owners.
Contacts:
Sangkil Lee, Ph.D.
Seegene Inc.
301-762-9066
Email Contact
or
Constantine Theodoropulos
Boston Communications
617-292-7319
Email Contact
Copyright 2008, Market Wire, All rights reserved.
-0-
